Epidemiological study of Anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections

Journal of the National Cancer Institute

Volumn 102, Issue 21, 2010, Pages 1653-1662

  Safaeian, Mahboobeh ^a   Porras, Carolina ^b   Schiffman, Mark ^a   Rodriguez, Ana Cecilia ^b   Wacholder, Sholom ^a   Gonzalez, Paula ^b   Quint, Wim ^c   Van Doorn, Leen Jan ^c   Sherman, Mark E ^a   Xhenseval, Valérie ^d   Lowy, Douglas R ^e   Hildesheim, Allan ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^c DDL Diagnostic Laboratory   (Netherlands)

^d GSK   (Belgium)

^e HPV Virologist   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY; VIRUS DNA; WART VIRUS VACCINE;

ADULT; AGE DISTRIBUTION; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COSTA RICA; DEMOGRAPHY; EDUCATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; INFECTION RISK; MAJOR CLINICAL STUDY; MARRIAGE; MEDICAL EXAMINATION; MEDICAL HISTORY; PAPILLOMAVIRUS INFECTION; POISSON DISTRIBUTION; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SERODIAGNOSIS; SEXUALITY; SMOKING; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION;

EID: 78149327887     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq384     Document Type: Article

References (26)

1. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol. 1995;69(6):3959-3963.
2. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci \USA. 1995;92(25):11553-11557.
3. Schiller JT, Lowy DR. Papillomavirus-like particles and HPV vaccine development. Semin Cancer Biol. 1996;7(6):373-382.
4. Paavonen J, Naud P, Salmeron J, et al. Effcacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and pre-cancer caused by oncogenic HPV types (PATRICIA): fnal analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686): 301-314.
5. Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst. 2001;93(4):284-292.
6. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347(21):1645-1651.
7. Paavonen J, Jenkins D, Bosch FX, et al. Effcacy of a prophylactic adju-vanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369(9580):2161-2170.
8. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-1943. (Pubitemid 46740303)
9. Future 11 Study Group. Quadrivalent vaccine against human papilloma-virus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19): 1915-1927.
10. Schiller JT, Lowy DR. Immunogenicity testing in human papillomavirus-like-particle vaccine trials. J Infect Dis. 2009;200(2):166-171.
11. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specifc implications in cervical neoplasia. Vaccine. 2008;26(suppl 10):K1-K16.
12. Ho GY, Studentsov Y, Hall CB, et al. Risk factors for subsequent cervicovagi-nal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis. 2002;186(6):737-742.
13. Viscidi RP, Schiffman M, Hildesheim A, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev. 2004;13(2):324-327.
14. Viscidi RP, Snyder B, Cu-Uvin S, et al. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev. 2005;14(1):283-288.
15. Herrero R, Hildesheim A, Rodriguez AC, et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine. 2008;26(37): 4795-4808.
16. Dessy FJ, Giannini SL, Bougelet CA, et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin. 2008;4(6):425-434.
17. Harper DM, Franco EL, Wheeler C, et al. Effcacy of a bivalent L1 viruslike particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364(9447):1757-1765.
18. Kleter B, van Doorn LJ, ter SJ, et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillo-maviruses. Am J Pathol. 1998;153(6):1731-1739.
19. Kleter B, van Doorn LJ, Schrauwen L, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identifcation of anogenital human papillomavirus. J Clin Microbiol. 1999;37(8):2508-2517.
20. Van Doorn LJ, Molijn A, Kleter B, Quint W, Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specifc PCR. J Clin Microbiol. 2006;44(9):3292-3298.
21. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009;199(7): 926-935.
22. Wheeler CM, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis. 2009;199(7):936-944.
23. Harper DM, Franco EL, Wheeler CM, et al. Sustained effcacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papilloma-virus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247-1255.
24. Kemp TJ, Garcia-Pineres A, Falk RT, et al. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine. 2008;26(29-30):3608-3616.
25. Wang SS, Schiffman M, Herrero R, et al. Determinants of human papilloma-virus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica. Br J Cancer. 2004;91(7):1269-1274.
26. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157(3): 218-226.